Our Exploding New Pick is Vivakor, Inc. VIVK http://www.vivakor.com/

VIVK is a trans-disciplinary biomedical/biotechnology company involved
in Discovering, Developing and Commercializing Solutions that
positively impact life. www.vivakor.com

VIVK plans to adapt a $300 Million potential technology upgrade to
produce and enhance MRI images which might improve MRI resolution
along with providing additional data such a blood flow velocity in
images tissues.

Market potential of about $15 Million just within 12 month
commercialization of the electro-optical devices released by VIVK.

VIVK have a fully integrated specialist team working on clinical trial
on Digital Photo screener, Opti-Ear and Anemia Monitor, having a
completion time of late 2009, positive results may drastically reduce
overall time and cost from previously used technology.

Experienced BOD Matthew Nicosia, Dr.Tannin Fuju and John Grayga have
strategically grown the revenue of VIVK from $20 Million to $120
Million. They approved a dividend to every share holders. Each share
holder will receive one HealthAmerica share for every share of Vivakor
Inc.

VIVK is currently in collaboration with University of IOWA, developing
a digital photo refractor that is intended to modernize child vision
screening. Approval has been granted from Western Institutional Review
Borad(20080731) to conduct human validation study.

VIVK has developed a series of nutraceutical formulations, including
VivaBlend, and plan to develop additional nutraceuticals, botanicals
and supplements. VIVK recently received 25000 units purchase order for
one of their products.

Critical advancement in the biological sample preservation are also
been evolved in VIVK. They have developed specialized Cryovials that
accommodate an improved method of cryopreservation of cells, blood and
other bio-materials.

VIVK have recently launched its sales products to Exploding Indian
Biotech market. Biopharma remains India’s biggest sector, accounting
for nearly 70% of the total revenues, expected to be worth US $5.7
Billion by 2012-2013. The future of the bio-supplier industry in India
looks very bright and so does of VIVK.

Check out Complete Presentation only at www.stockexploder.com

Please do your own due diligence on VIVK
All The Best

Exploder

www.stockexploder.com

 *Never invest in a stock mentioned by stockexploder.com unless you
can afford to lose your entire investment. For full disclaimer
http://www.stockexploder.com/disclaimer.html
Reply

Reply to all

Forward

sto

SINOBIOPHRMA INC "soared" 93% with two trading Days after my alert !
Congratulations!!!

Today SINOBIOPHRMA INC traded as high of  0.39 on over 5,000,000
shares traded

I gave this to you at 0.20 for Monday's trade....

Ok, so what’s next you ask? I have something even bigger...

Why it's in your best interest to buy  and Full Presentation on Entest
BioMedical Inc

Bio-tech companies are a great investment right now, according to many
financial experts. Support from the Obama administration will ensure
this trend continues.

Between the current administration rallying behind Bio-tech and
Stimulus plan. This is a great combo to ensure if you pick the right
Bio-tech stock you can make massive gains quickly.

"WALL STREET IS ALWAYS LOOKING” For the Next Big Thing.......

Whether it's a cure for cancer or a fountain of youth , the script
can be all-too-familiar Financially, 2009 has been a hard year.

Almost every industry sector has suffered....

But financial experts wouldn't be experts if they couldn't find a
sector that will do better than the others, and that will offer
substantial returns

to investors.

Biotech is what they recommend

Forbes interviewed two top-notch analysts in this area, Eric Schmidt
and Ross Muken. They both agree that there is money to be made by
investing in biotech.

Bottom line is this... You have a choice,

You can take action and buy Entest BioMedical Inc now!
or wait to buy it at potentially $3.50 per share

This is set to soar!!

Exploder

SNBP is our New Pick www.sinobiopharma.com

SINO BIOPHARMA SNBP a Fully integrated specality biopharmaceutical
company with 30,000 sq.meter Certified Production Facilities in China.

Estimated Chinese Health Care Market Demand of $600 Billion by 2015.We
all are aware China’s Current population is 1.4 Billion.

SNBP traded as high as $2.0 in the PAST, we can shoot for a gain of
8400%

Leadership of CEO Dr. Lequn Lee Huang a former manager of the Bayer
Co., one of the world's largest pharmaceutical companies and CFO Mr.
Dong Ying formerly of JP Morgan Chase.

SNBP Anesthetics Projected sale of 1.5 million units and 500,000
tablets for cardiovascular diseases in 2009.

Key Drives:
Outstanding financial results; more than 2000% growth in 3 years.
4 key marketed products; multiple products in pipeline.
R&D Partnership with Cornell University and 3 Top Universities in
China.
Established Nation wide Sales and Marketing Network in China.
Aging Population & Increasing Life Style diseases.
Improving Health Insurance Programs and Coverage.

PLAN FOR FUTURE: Sinobiopharma has a clearly defined strategy to drive
short, middle and long term growth.  All drug development will
leverage the Company's patented technology for fast, low-cost drug
synthesis and new technology for formulation.

Check out Complete Presentation only at www.stockexploder.com
Please do your own due diligence on SNBP
All The Best

Exploder

www.stockexploder.com
 *Never invest in a stock mentioned by stockexploder.com unless you
can afford to lose your entire investment. For full disclaimer
http://www.stockexploder.com/disclaimer.html

Such earnings also would also trigger long term holders to sell it
because it will be harder for CAAS to top itself next year.

On Nov 12, 11:14 am, fortunegame <www...@hotmail.com> wrote:

On Nov 12, 10:47 am, JimA <jame...@yahoo.com> wrote:

Trees do not grow to sky.  It gained too much and too fast.

CAAS share price has gained 70% in two weeks.  I see it will gradually
correct itself.

I will wait at least two months to consider it.  Don't want to
overpay.

On Nov 12, 9:03 am, fortunegame <www...@hotmail.com> wrote:

On Nov 12, 8:51 am, fortunegame <www...@hotmail.com> wrote:

http://hotstockstowatch.blogspot.com/

On Aug 12, 4:57 pm, Jerry <jerrybuf...@gmail.com> wrote:

On Aug 12, 2:01 pm, Ivan Barreto <pennystockisri...@gmail.com> wrote:

On Aug 12, 1:18 pm, Justin Cage <cagemonste...@gmail.com> wrote:

So it can be a good pick depending on your methodology.

My firm deals with a computer software system that automatically buys
and sells stock indices and commodities. So it makes money when the
stock market is going up, down, or sideways.  It uses successful
algorithmic trading patterns. It makes money in volatile markets, when
most people are losing money, with very little risk.

I cannot give out all of the details right now.

What I can tell you is that it has been averaging 20% return per month
consistently for the past 18 months (360% total). The worst month
return was a 1% loss in September of 2006 and its best month was a 94%
gain in October in its 3.5 year track history.

One of my assistants will be able to give you information to see if
this makes sense for you. In order to qualify, you must have a minimum
of $15,000 of capital and you must read and follow the instructions on
the bottom of this page or you will not get a response.

I can't give out all the details, publicly, but if you are interested
email Eric at:

primetradingsys...@gmail.com

*** PLEASE READ INSTRUCTIONS IN ITS ENTIRETY ***

I am extremely busy with clients, so you MUST request an appointment
to call me Monday through Friday between 9 AM and 5 PM EST.  One of my
assistants will tell you whether or not I am available that day. Also,
my assistants will NOT respond to any email with general questions if
an appointment is not set.